Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2017 · 10-Q
Revenue$15.00K$15.00K−96.4% vs Q2 2016 Net Income-$7.38M-$7.38MN/M vs Q2 2016 EPS Diluted-$0.41-$0.41N/M vs Q2 2016 Operating Income-$7,893,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,903,000N/M Margins · derivedOperating margin-52620.0%−51078.6 pt vs Q2 2016
Net margin-49200.0%−47743.3 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 3, 2017 · 34 d after period end